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Summary
Background: Abnormal coronary response on acetylcholine test is observed in patients with
early coronary atherosclerosis.
Objectives: We analyzed retrospectively the abnormal response rate during 17 years of spasm
provocation tests in 2093 consecutive patients.
Methods: We performed 2093 spasm provocation tests, consisting of 1198 acetylcholine tests
and 895 ergonovine tests, between January 1991 and December 2007. Spasm provocation test
was mainly performed in patients with ischemic heart disease. Abnormal response was deﬁned
as transient >90% luminal narrowing during spasm provocation tests. We classiﬁed these 17 years
into two periods: former period from January 1991 to December 2000, and the latter period
from January 2001 to December 2007. In the former period, 1300 spasm provocation tests were
performed and 793 spasm provocation tests were done in the latter period.
Results: The incidences of hypertension, dyslipidemia, and diabetes mellitus were signiﬁ-
cantly increased in the latter period. The values of total cholesterol, triglycerides, and fasting
blood sugar were also signiﬁcantly increased in the latter period. The frequency of abnormal
response in the latter period was signiﬁcantly higher than that in the former period (46.0%
vs. 33.2%, p < 0.05). The frequency of abnormal coronary response to acetylcholine in the
latter period was signiﬁcantly higher than that in the former period (60.0% vs. 34.0%, p < 0.01),
∗ Corresponding author at: The Department of Cardiology, Ehime Niihama Prefectual Hospital, Hongou 3 choume 1-1, Niihama City,
hime 792-0042, Japan. Tel.: +81 897 43 6161; fax: +81 897 41 2900.
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whereas there was no difference concerning abnormal response of ergonovine between the two
periods (31.9% vs. 30.7%, ns).
Conclusions: In Japanese patients, abnormal coronary response to acetylcholine has increased
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dynamic instability due to the coronary spasm occurred,
2.5—5.0mg of isosorbide dinitrate was injected into theand coronary endothelial dys
© 2010 Published by Elsevier
Introduction
As spasm provocation agents, we have employed intracoro-
nary administration of acetylcholine (ACh) and ergonovine
(ER) since the latter half of the 1980s. In 1986 and 1988,
Yasue et al. [1] and Okumura et al. [2,3] reported the use-
fulness of intracoronary administration of ACh as a spasm
provocation test, while Hackett et al. [4] also reported the
intracoronary administration of ER as a spasm provocation
test in 1987. We have already reported the incidence of pro-
voked spasms in patients undergoing coronary arteriography
with spasm provocation tests using ACh and ER [5—7].
ACh dilates if the artery has no atherosclerosis, whereas
ACh constricts coronary artery if the artery has mild
atherosclerosis [8,9]. Thus, the coronary artery showing
abnormal response to ACh has endothelial dysfunction at
least. Recently, coronary artery endothelial dysfunction has
increased due to the increase in hypertension, dyslipidemia,
and diabetes mellitus associated with the metabolic syn-
drome even in Japan [10].
This study sought to compare the annual incidence of
abnormal coronary response by intracoronary administration
of ACh and ER retrospectively over 17 years. We also com-
pared the relationship between abnormal coronary response
and coronary risk factors.
Methods
Study patients
We performed selective spasm provocation tests to exam-
ine the incidence of provoked spasm in Japanese patients
who had undergone ﬁrst coronary angiography. Between
January 1991 and December 2007, we performed 2093 selec-
tive ACh and ER spasm provocation tests. The provocation
test was not performed if patients had left main narrowing
(>50%), triple-vessel disease, two-vessel disease with total
occlusion, heart failure (New York Heart Association func-
tional class III or IV), renal failure (creatinine >2.0mg/dl),
if spontaneous spasms were observed, or if isosorbide dini-
trate was initially used to relieve spasms in the coronary
artery tested. We also did not perform spasm provoca-
tion tests if the patients were due to undergo coronary
angioplasty or bypass surgery. Thus, ﬁnal study subjects
were 2093 patients (1386 men, mean age 64.9± 10.3 years)
without the above exclusion criteria. Selective spasm provo-
cation tests using ACh were performed in 1198 patients
(832 men, mean age 64.3± 10.1 years) and using ER
in 895 patients (554 men, mean age 65.6± 10.7 years)
(Table 1).
As shown in Table 2, patients were classiﬁed into eight
groups based on the clinical diagnosis, according to pre-
vious reports [5—7]. We classiﬁed these periods into two
phases, consisting of former procedures done between 1991
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3tion is suggested to have progressed.
nd Ltd on behalf of Japanese College of Cardiology.
nd 2000, and of latter procedures performed between 2001
nd 2007 with each agent.
The procedure was explained in detail to each patient,
nformed consent was obtained, and the protocol of this
tudy was in agreement with the guidelines of the ethical
ommittee at our institution.
The diagnosis of typical angina was made in patients
eeting all of the following criteria: (1) retrosternal burn-
ng or squeezing chest pain; (2) quick relief of pain (<5min)
fter administration of sublingual nitroglycerin; (3) chest
ain thought to have myocardial ischemia as its source.
Ch and ER spasm provocation test
oronary arteriography was obtained by injection of
—10mL of contrast medium with the Sones technique from
0:00 h to 16:00 h with no medication for at least 24 h. A
ipolar electrode catheter was inserted into the right ven-
ricular apex through the femoral vein or antecubital vein
nd was connected to a temporary pacemaker set at the
ate of 45 beats/min.
Provocation of coronary artery spasm was performed
ith an intracoronary injection of ACh and ER, as pre-
iously reported [5—7,11,12]. ACh chloride (Neucholin-A,
0mg/2mL; Zeria Seiyaku, Tokyo, Japan) was injected in
ncremental doses of 20, 50, and 80g into the right
oronary artery and of 20, 50, and 100g into the left
oronary artery over 20 s with at least a 3-min interval
etween each injection. Coronary arteriography was per-
ormed when either ST-segment changes or chest pain (or
oth) occurred, or after 1min following the completion
f each injection. Intracoronary injection of ACh into the
esponsible vessel was not performed if coronary artery
pasm occurred spontaneously during coronary angiogra-
hy. ER (ergometrine injection F, 0.2mg/mL; Fuji Seiyaku,
okyo, Japan) in 0.9% warm saline solution was injected
n 10g/min for 4min for a maximal dose of 40g into
he right coronary artery and 16g/min over 4min for a
otal dose of 64g into the left coronary artery, with at
east a 5-min interval between each injection. If systolic
lood pressure was >190mmHg before performing ER tests,
e did not perform ER tests in these patients. Coronary
rteriography was performed when ST-segment changes,
hest pain (or both), occurred, or following 2min after the
ompletion of each injection. When a coronary spasm was
nduced and did not resolve spontaneously within 3min after
he completion of ACh and ER injection, or when hemo-esponsible vessel. During the study, arterial blood pressure
nd an electrocardiogram lead (II) were continuously mon-
tored on an oscilloscope using a Nihon-Kohden polygraph.
standard 12-lead electrocardiogram was recorded every
0 s.
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Table 1 Patients’ characteristics.
Acetylcholine Ergonovine Total
Number of patients 1198 895 2093
Male 832 (69.4)* 554 (61.9) 1386 (66.2)
Age (year) 64.3± 10.1 65.6± 10.7 64.9± 10.3
Organic stenosis (>75%) 314 (26.2) 232 (25.9) 546 (26.1)
Hypertension 516 (43.1) 388 (43.4) 904 (43.2)
Smoking history 795 (66.4)* 492 (55.0) 1287 (61.5)
Dyslipidemia 462 (38.6) 327 (36.5) 789 (37.7)
Diabetes mellitus 229 (19.1) 165 (18.4) 394 (18.8)
Total cholesterol (mg/dl) 190.9± 35.0 193.3± 35.7 192.0± 35.3
Triglyceride (mg/dl) 132.5± 77.9 131.8± 88.3 132.2± 82.8
HDL-cholesterol (mg/dl) 46.9± 13.2 48.1± 13.0 47.4± 13.1
LDL-cholesterol (mg/dl) 115.4± 30.1 116.8± 30.2 116.1± 30.1
Fasting blood sugar (mg/dl) 109.8± 39.6 111.8± 40.5 110.7± 40.0
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HDL, high-density lipoprotein; LDL, low-density lipoprotein; value
* p < 0.01 vs. other.
In this study, we performed frequent test shots at about
0-s intervals with a contrast medium during ACh and ER
esting, if possible. We tried to perform coronary angiogra-
hy before complete spasms were induced by pharmacologic
gents.
We also examined the relationship between abnormal
oronary response and age, gender, smoking, and coronary
isk factors. Dyslipidemia was deﬁned as either a cholesterol
evel >220mg/dl or a triglyceride level >150mg/dl. Diabetes
ellitus was deﬁned according to the World Health Organi-
ation criteria [13]. Systemic hypertension was deﬁned as
ither a systolic blood pressure of >140mmHg or a diastolic
lood pressure of >90mmHg or as patients already treated
ith antihypertensive drugs [14]. A smoking history was
e
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Table 2 Comparison of proportion of patients undergoing acetylc
Group Clinical diagnosis
Ischemic heart disease
A Angina at rest
B1 Angina on effort
B2 Angina on both
C1 Acute myocardial infarction
C2 Old myocardial infarction
D Post PCI
Non-ischemic heart disease
E Atypical chest pain
F Valvular heart disease
G1 Cardiomyopathy (dilated)
G2 Hypertrophic cardiomyopathy
H Other
Total
PCI, percutaneous coronary intervention.
* p < 0.01 vs. other.
** p < 0.01 vs. other.5.52± 1.20 5.47± 1.09
hin parentheses are in %.
btained from all the patients on admission. In this study, >5
ears’ habitual smoking in the past was considered positive.
ngiographic analysis
he coronary arteriograms were analyzed separately by two
ndependent observers. The percent luminal diameter nar-
owing of coronary arteries was measured by an automatic
dge-contour detection computer analysis system (CARDIO
00, Kontron Instruments, Tokyo, Japan). The size of the
oronary catheter was used to calibrate the image in mil-
imeters, and the measurement was performed in the same
oronary angiography projection at each stage. Abnormal
holine and ergonovine tests.
Proportion of patients [n (%)]
Acetylcholine Ergonovine
1991—2000 2001—2007 1991—2000 2001—2007
494 (63.1) 285 (68.7) 337 (65.2) 234 (61.9)
163 (20.8) 140 (33.7)* 106 (20.5) 92 (24.3)
77 (9.8) 33 (8.0) 59 (11.4) 38 (10.1)
60 (7.7) 20 (4.8) 35 (6.8) 29 (7.7)
82 (10.5)* 22 (5.3) 46 (8.9)* 16 (4.2)
41 (5.2) 39 (9.4)* 36 (7.0) 32 (8.5)
71 (9.1) 31 (7.5) 55 (10.6) 27 (7.1)
289 (36.9) 130 (31.3) 180 (34.8) 144 (38.1)
94 (12.0)** 34 (8.2) 91 (17.6) 53 (14.0)
34 (4.3)** 8 (1.9) 6 (1.2) 6 (1.6)
37 (4.7) 11 (2.7) 9 (1.7) 7 (1.9)
22 (2.8) 10 (2.4) 10 (1.9) 8 (2.1)
102 (13.1) 67 (16.1) 64 (12.4) 70 (18.5)**
783 415 517 378
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AFigure 1 Annual transition of abnormal response rate
coronary response was assessed as >90% luminal narrow-
ing. Patients with catheter-induced spasms were excluded
from this study. Signiﬁcant organic stenosis was deﬁned as
>75% luminal narrowing according to the American Heart
Association (AHA) classiﬁcation [15]. Coronary arteries were
measured after intracoronary administration of isosorbide
dinitrate (5.0mg) to evaluate coronary atherosclerosis.
Statistical analysis
All values are expressed as mean± SD. Clinical characteris-
tics between patients with and without abnormal response
and differences among proportions were analyzed by the 2
test with correction or the ANOVA test. The spasm frequency
was compared by use of Yates’ corrected 2 test or Fisher’s
exact test as appropriate. A value of p < 0.05 was considered
statistically signiﬁcant.
Results
Proportion of patients receiving two agents
As shown in Table 1, the frequency of male gender and
history of smoking was signiﬁcantly higher in patients
receiving ACh than in those receiving ER. However, other
items including the values of total cholesterol, triglyc-
eride, high-density lipoprotein-cholesterol, low-density
lipoprotein-cholesterol, fasting blood sugar, and glycohe-
moglobin was not different between the two groups.
As shown in Table 2, the proportion of ischemic heart
disease and non-ischemic heart disease was not different
between the two periods on both agents. However, in ACh
testing, the incidence of patients with angina at rest and
old myocardial infarction was frequently observed in the lat-
ter period (2001—2007), whereas the frequency of patients
with acute myocardial infarction, atypical chest pain, and
valvular heart disease was signiﬁcantly higher in the for-
mer period (1991—2000). In ER testing, the incidence of
patients with acute myocardial infarction was more fre-
quently observed in the former period than in the latter
F
i
b
c
oeen the two agents. (A) Acetylcholine. (B) Ergonovine.
eriod, while the frequency of patients with other diagnoses
as signiﬁcantly higher in the latter period than in the for-
er period. Although a retrospective study, the distribution
f ischemic and non-ischemic heart disease in both periods
as similar to that on both tests.
nnual transition of abnormal response rate on
oth agents
s shown in Fig. 1, the incidence of abnormal response in
Ch testing signiﬁcantly and gradually increased, while the
requency of abnormal response in ER tests was not different
uring 17 years.
bnormal coronary response and coronary risk
actors
summary of coronary risk factors is shown in Table 3. On
oth tests, the incidence of hypertension, dyslipidemia, and
iabetes mellitus was signiﬁcantly increased in 2001—2007
ompared with that in 1991—2000. The values of total
holesterol, triglyceride, fasting blood sugar, and high-
ensity lipoprotein-cholesterol were signiﬁcantly increased
n 2001—2007. In ACh testing as shown in Table 4, the inci-
ence of male gender, history of smoking, and dyslipidemia
as signiﬁcantly higher in patients with abnormal response
han those without, while the incidence of male gender and
istory of smoking was frequently observed in patients with
bnormal response compared with those without.
requency of abnormal response in patients with
nd without IHD
summary of the results of all 2093 patients is shown in
ig. 2 and Table 5. Table 5 shows that in patients with
schemic heart disease, the frequency of abnormal response
y intracoronary injection of ACh in 2001—2007 was signiﬁ-
antly higher than that in 1991—2000, whereas the incidence
f abnormal response by ER test was not different between
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Table 3 Comparison of coronary risk factors between the two periods.
Acetylcholine Ergonovine
1991—2000 2001—2007 1991—2000 2001—2007
Number of patients 783 415 517 378
Male 533 (68.1) 299 (72.0) 322 (62.3) 232 (61.4)
Age (year) 63.3± 9.6 66.1± 10.7 64.0± 10.3 67.9± 10.5
Organic stenosis 214 (27.3) 100 (24.1) 142 (27.5) 90 (23.8)
Hypertension 315 (40.2) 201 (48.4)* 200 (38.7) 188 (49.7)*
Smoking history 512 (65.4) 283 (68.2) 278 (53.8) 213 (56.3)
Dyslipidemia 257 (32.8) 205 (49.4)* 140 (27.1) 187 (49.5)*
Diabetes mellitus 129 (16.5) 100 (24.1)* 84 (16.2) 81 (21.4)**
Total cholesterol (mg/dl) 184.5± 32.5 196.7± 36.3* 186.2± 32.8 199.8± 36.6*
Triglyceride (mg/dl) 129.0± 64.1 135.5± 87.7* 124.4± 59.3 138.2± 106.7
HDL-cholesterol (mg/dl) 43.6± 12.4 49.6± 13.3* 46.5± 12.0 49.3± 13.7*
LDL-cholesterol (mg/dl) 116.0± 28.2 114.8± 31.7 115.2± 29.6 118.3± 30.7
Fasting blood sugar (mg/dl) 101.2± 29.6 117.2± 45.2* 105.6± 34.7 117.7± 45.5*
Glycohemoglobin (%) 5.31± 0.84 5.52± 1.08 5.53± 1.14 5.52± 1.23
HDL, high-density lipoprotein; LDL, low-density lipoprotein; values within parentheses are in %.
* p < 0.01 vs. 1991—2000.
** p < 0.05 vs. 1991—2000.
Table 4 Comparisons of sex and coronary risk factors in patients with and without abnormal response.
Acetylcholine Ergonovine
Negative Positive Negative Positive
Number of patients 683 515 614 281
Male 418 (61.2) 414 (80.4)* 310 (50.5) 244 (86.8)*
Hypertension 289 (42.3) 227 (44.1) 274 (44.6) 114 (40.6)
Smoking history 389 (57.0) 406 (78.8)* 270 (44.0) 221 (78.6)*
Dyslipidemia 223 (32.7) 239 (46.4)* 217 (35.3) 110 (39.1)
Diabetes mellitus 122 (17.9) 107 (20.8) 107 (17.4) 58 (20.6)
Values within parentheses are in %.
* p < 0.01 vs. each negative group.
Figure 2 Comparison of the frequency of abnormal response in various cardiac disorders between the two agents. (A)
Acetylcholine. (B) Ergonovine. R&E, rest and effort; AMI, acute myocardial infarction; OMI, old myocardial infarction; Post P,
post-percutaneous coronary intervention; HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; Val, valvular heart
disease.
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Table 5 Comparisons of the frequency of abnormal response in patients with and without ischemic heart disease.
IHD Non-IHD All
ACh
1991—2000 234/494 (47.4) 32/289 (11.1) 266/783 (34.0)
2001—2007 208/285 (73.0)* 41/130 (31.5)* 249/415 (60.0)*
ER
1991—2000 152/337 (45.1) 13/180 (7.2) 165/517 (31.9)
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12001—2007 87/234 (37.2)
IHD, ischemic heart disease; Ach, acetylcholine; ER, ergonovine.
* p < 0.01 vs. 1991—2000 each.
the two periods. In contrast, in patients with non-ischemic
heart disease, the frequency of abnormal responses in
2001—2007 was signiﬁcantly higher than that in 1991—2000
on both tests.
Frequency of abnormal response in ACh test
As shown in Fig. 2, the frequency of abnormal response in
various cardiac disorders, such as angina on effort [35.1%
(27) vs. 54.5% (18), ns], on both rest and effort [50.0%
(30) vs. 75.0% (15), ns], acute myocardial infarction [42.7%
(35) vs. 59.1% (13), ns], valvular heart disease [11.8% (4)
vs. 37.5% (3), ns], dilated cardiomyopathy [5.4% (2) vs.
18.2% (2), ns], and hypertrophic cardiomyopathy [18.2%
(4) vs. 20.0% (2), ns] was not different between the two
periods. The frequency of abnormal response in patients
with rest angina [62.0% (101) vs. 80.7% (113), p < 0.01], old
myocardial infarction [39.0% (16) vs. 64.1% (25), p < 0.05],
post-percutaneous coronary intervention (PCI) [35.2% (25)
vs. 77.4% (24), p < 0.01], atypical chest pain [7.4% (7) vs.
23.5% (8), p < 0.05], and other groups [14.7% (15) vs. 40.6%
(26), p < 0.01] was signiﬁcantly higher in 2001—2007 than in
1991—2007.
Frequency of abnormal response in ER testAs shown in Fig. 2, the frequency of abnormal response in
various cardiac disorders, such as angina at rest [54.7% (58)
vs. 48.9% (45), ns], on effort [30.5% (18) vs. 18.4% (7), ns], on
both [45.7% (16) vs. 48.3% (14), ns], acute myocardial infarc-
A
A
a
Table 6 Comparison of abnormal response vessel between the tw
Acetylcholine
1991—2000
Site of abnormal response vessel
Right coronary artery 164 (41.8)
Left circumﬂex artery 60 (15.3)
Left anterior descending artery 168 (42.9)
Total 392
1 abnormal response vessel (right) 164 (61.7)*
2 abnormal response vessel (right) 78 (29.3)
3 abnormal response vessel (right) 24 (9.0)
2 and 3 abnormal response vessel 102 (38.3)
Values within parentheses are in %.
* p < 0.01 vs. other.29/144 (20.1)* 116/378 (30.7)
ion [37.0% (17) vs. 25.0% (4), ns], old myocardial infarction
47.2% (17) vs. 25.0% (8), ns], after PCI [47.3% (26) vs. 33.3%
9), ns], atypical chest pain [4.4% (4) vs. 15.1% (8), ns],
alvular heart disease [16.7% (1) vs. 50.0% (3), ns], dilated
ardiomyopathy [0% (0) vs. 14.3% (1), ns], hypertrophic car-
iomyopathy [20.0% (2) vs. 37.5% (3), ns], and other groups
9.4% (6) vs. 20.0% (14), ns] was not different between the
wo periods.
requency of abnormal response in overall results
summary of the results of all 2093 patients is shown in
able 5. The frequency of abnormal response in patients
ith and without ischemic heart disease with ACh tests
uring 2001—2007 was signiﬁcantly higher than that dur-
ng 1991—2000, while the frequency of abnormal response
ith ER tests during 1991—2000 was not different from
hat during 2001—2007. However, the frequency of abnor-
al response with ER tests during 2001—2007 in patients
ithout ischemic heart disease was signiﬁcantly higher than
hat during 1991—2000 and no difference was found between
he two periods in patients with ischemic heart disease.
n overall results, the incidence of abnormal response dur-
ng 2001—2007 was signiﬁcantly higher than that during
991—2000.bnormal response site and vessel number
s shown in Table 6, the distribution of abnormal response
rtery was not different between the two periods with
o periods in acetylcholine and ergonovine tests.
Ergonovine
2001—2007 1991—2000 2001—2007
213 (43.5) 95 (45.5) 77 (48.5)
81 (16.6) 32 (15.3) 26 (16.3)
195 (39.9) 82 (39.2) 56 (35.2)
489 209 159
73 (29.3) 128 (77.6) 79 (68.1)
112 (45.0)* 30 (18.2) 31 (26.7)
64 (25.7)* 7 (4.2) 6 (5.2)
176 (70.7)* 37 (22.4) 37 (31.9)
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oth agents. Multiple abnormal responses induced by ACh
est was signiﬁcantly higher in 2001—2007 than that in
991—2000, while there was no difference in both periods
etween one-vessel abnormal response and multiple-vessel
bnormal response with ER.
iscussion
he present study was the ﬁrst to compare the annual
requency of abnormal coronary responses between ACh
nd ER in a large group of patients who underwent
oronary arteriography over 17 years. The frequency of
bnormal coronary responses with ACh tests increased
igniﬁcantly over time. The frequency of abnormal mul-
iple responses by ACh tests also increased signiﬁcantly
ith increasing time. ACh dilates the coronary artery if
he artery has no atherosclerosis and normal endothe-
ial function, whereas ACh constricts the coronary artery
f the artery has a certain degree of atherosclerosis and
ndothelial dysfunction. Thus, coronary arteries showing
bnormal responses by ACh tests have at least some initial
therosclerosis. In Japanese patients who underwent coro-
ary arteriography, coronary endothelial dysfunction had
ertainly progressed during the 17 years. This may be due to
gradual increase in coronary risk factors, such as hyperten-
ion, dyslipidemia, and diabetes mellitus. This phenomenon
bserved in the present study in Japan may apply to other
riental countries, such as Korea, Chinese Taipei, and
hina.
ecessity of investigation of abnormal coronary
esponse
e previously reported the reduced frequency of variant
ngina due to the widespread use of calcium antago-
ists in Japan [16]. In the present study, the frequency
f coronary spastic angina in patients who had undergone
oronary arteriography did not decrease with increasing
ime.
In the USA and Europe, routine investigation of coro-
ary artery spasm in patients with ischemic heart disease is
ot recommended [17]. The prevalence of coronary artery
pasm in Japan is three times higher than that in the USA or
urope [5,6,18—21]. About 20 years ago, the spasm provo-
ation test was carried out in most cardiology institutions
n Japan. Recently, some Japanese cardiologists have been
nterested in performing PCI and paid no attention to per-
orm spasm provocation tests due to their daily overwork
nd its intricacy [22].
In general, cardiologists tend to carry out PCI with-
ut investigation of coronary artery spasm. Coronary artery
pasm may cause transient ischemic events, such as acute
oronary syndrome, sudden cardiac death, serious arrhyth-
ia and syncope, and organic stenosis. Cardiologists may
iss the real cause of ischemic events in patients sus-
ected of ischemic heart disease. If we carried out PCI
n all patients with organic stenosis, ischemic episodes
ould still occur. The usefulness of spasm provocation tests
nd the necessity of the investigation of coronary artery
pasm in diagnosing patients with ischemic heart disease
F
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hould be taught to cardiologists in training in Oriental
ountries.
ecessity of statin and diet therapy
he frequency of coronary artery spasm may decrease due
o the administration of statins according to the report of
asue et al. [23]. Coronary artery spasmmay decrease due to
he effect of statins because of Rho-kinase inhibition. Statin
dministration may reduce the level of total cholesterol
nd low-density lipoprotein-cholesterol, and may improve
ndothelial dysfunction and reduce the incidence of abnor-
al responses by pharmacologic agents. The decreasing
evel of total cholesterol and blood sugar may improve coro-
ary endothelial function. These effects may lead to the
mprovement of coronary endothelial dysfunction.
linical implications
e should investigate coronary artery spasm in patients with
nd without ischemic heart disease when carrying out car-
iac catheterization. We should lower the level of total
holesterol, triglycerides, and blood sugar. If the prevalence
f dyslipidemia and diabetes mellitus decreases in the near
uture in Japan, the prevalence of abnormal responses may
all and coronary endothelial dysfunction may improve.
The prevalence of abnormal coronary responses by ER
as not different in proportion as time passed. Damage
o coronary vascular smooth muscle may not always be
bserved. Coronary endothelial dysfunction may be fre-
uently recognized in Japanese patients. If ACh and ER
ad an identical pharmacological reaction, the incidence
f abnormal coronary responses was not different between
he two agents [24]. Initial coronary atherosclerosis such as
ntimal hyperplasia and localized plaques may lead to coro-
ary artery endothelial dysfunction. Nevertheless, abnormal
oronary response due to pharmacologic agents (ACh and ER)
oes not always lead to coronary artery spasm.
tudy limitations
ur study had several limitations. The ﬁrst was that this
as a retrospective and non-randomized study design and
either test was performed in consecutive patients. The sec-
nd limitation was that medication was not discontinued for
everal days before the ACh and ER tests. The third limita-
ion was the dose of ACh and ER in the spasm provocation
ests. If higher doses than used in this study were employed,
he frequency of abnormal coronary response might be dif-
erent from these results. The fourth limitation was that
he proportion of various cardiac disorders was not always
qual between the two periods on both agents. However,
he proportion between ischemic and non-ischemic heart
isease was not different in each period with both agents.
urther study is necessary to investigate the pathophysiology
f abnormal coronary response induced by pharmacologic
gents. Moreover, further study is also necessary to investi-
ate the incidence of abnormal coronary response in larger
roups of patients over 20 years, including Caucasian and
riental patients.
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